GEMFIBROZIL
- Product NDC
- 42806-260
- 11-digit product format
- 428060260
- Labeler code
- 42806
- Product ID
- 42806-260_e33e6a91-1c1d-4692-b3fb-1ac5776d480b
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- GEMFIBROZIL
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Epic Pharma, LLC
- Application
- ANDA078012
- Marketing category
- ANDA
- Marketing start
- 2017-03-23
- Marketing end
- 0000-00-00
- Substance
- GEMFIBROZIL
- Active strength
- 600 mg/1
- Pharmacologic classes
- PPAR alpha [CS], Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 42806-260-05 | GEMFIBROZIL | 500 in 1 BOTTLE | TABLET | 500 | | 9 |
| 42806-260-18 | GEMFIBROZIL | 180 in 1 BOTTLE | TABLET | 180 | | 9 |
| 42806-260-60 | GEMFIBROZIL | 60 in 1 BOTTLE | TABLET | 60 | | 9 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 42806-260 | GEMFIBROZIL TABLET [EPIC PHARMA, LLC] | 9 | Legacy NDC, 3 package rows | 20231228_77bb947a-340c-4592-b56d-bc77fb17e753.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 42806-260-05 | 42806026005 | 500 TABLET in 1 BOTTLE (42806-260-05) | 500 tablet | 2017-03-23 | 0000-00-00 | No | No | Current |
| 42806-260-18 | 42806026018 | 180 TABLET in 1 BOTTLE (42806-260-18) | 180 tablet | 2017-03-23 | 0000-00-00 | No | No | Current |
| 42806-260-60 | 42806026060 | 60 TABLET in 1 BOTTLE (42806-260-60) | 60 tablet | 2017-03-23 | 0000-00-00 | No | No | Current |